The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial

Atherosclerosis

Volumn 146, Issue 2, 1999, Pages 369-379

  Alaupovic, Petar ^a   Fesmire, Jim D ^a   Hunnighake, Donald ^b   Domanski, Michael ^c   Forman, Sandra ^d   Knatterud, Genell L ^d   Forrester, James ^e   Herd, J Alan ^f   Hoogwerf, Byron ^g   Campeau, Lucien ^h   Gobel, Fredarick L ⁱ  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Lipids; Lipoprotein families; Lovastatin; Saphenous vein grafts; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN; COLESTYRAMINE; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; TRIACYLGLYCEROL; WARFARIN;

ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; APOLIPOPROTEINS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; CORONARY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; LIPIDS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; SAPHENOUS VEIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0032870293     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00151-3     Document Type: Article

References (45)

1. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New Engl J Med. 336:1997;153-162.
2. Report of the National Cholesterol Education Program. Arch Intern Med. 148:1988;36-69.
3. The Coronary Primary Prevention Trial: design and implementation. J Chronic Dis. 32:1979;609-631.
4. Lipid Research Clinics Program: manual of laboratory operations. Lipid and Lipoprotein, Vol. 1. 1974;National Institutes of Health, Bethesda, MD. Analysis DHEW publication no. (NIH) 75-628.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
6. Fesmire J.D., McConathy W.J., Alaupovic P. Use and significance of reference serum as a secondary standard for electroimmunoassay of apolipoprotein A-I. Clin Chem. 30:1984;712-716.
7. Curry M.D., Gustafson A., Alaupovic P., McConathy W.J. Electroimmunoassay, radioimmunoassay, and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B. Clin Chem. 24:1978;280-286.
8. Curry M.D., McConathy W.J., Fesmire J.D., Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta. 617:1980;505-513.
9. Wieland H., Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res. 24:1983;904-909.
10. Alaupovic P. David Rubenstein Memorial Lecture: the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem. 59:1981;565-579.
11. Alaupovic P., Fernandes J. The serum apolipoprotein profile of patients with glucose-6-phosphatase deficiency. Pediatr Res. 19:1985;380-384.
12. Warnick G.R., Albers J.J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76.
13. 3H] cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs. Biochim Biophys Acta. 963:1988;534-540.
14. 2 and the other apolipoprotein B-containing lipoproteins with lipoprotein(a). J Biol Chem. 263:1988;6337-6343.
15. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res. 30:1991;105-138.
16. Parra H.J., Mezdour H., Ghalim N., Bard J.M., Fruchart J.C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem. 36:1990;1431-1435.
17. Bekaert E.D., Alaupovic P., Knight-Gibson C., Blackett P., Ayrault-Jarrier M. Composition of plasma ApoA-I-containing lipoprotein particles in children and adults. Pediatr Res. 29:1991;315-321.
18. Alaupovic P., Hodis H.N., Knight-Gibson C., Mack W.J., LaBree L., Cashin-Hemphill L., Corder C.N., Kramsch D.M., Blankenhorn D.H. Effects of lovastatin on apoA- and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb. 14:1994;1906-1914.
19. Koren E., Puchois P., Alaupovic P., Fesmire J., Kandoussi A., Fruchart J.-C. Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem. 33:1987;38-43.
20. Havekes L.M., de Knijff P., Beisiegel U., Havinga J., Smit M., Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 28:1987;455-463.
21. Luley C., Baumstark M.W., Wieland H. Rapid apolipoprotein E phenotyping by immunofixation in agarose. J Lipid Res. 32:1991;880-883.
22. Hallman D.M., Boerwinkle E., Saha N., Sandholzer C., Menzel H.J., Csázár A., Utermann G. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 49:1991;338-349.
23. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould A.L., Hesney M., Higgins J., Hurley D.P., Langendorfer A., Nash D.T., Pool J.L., Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. 1. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
24. Jacob B.G., Möhole W., Richter W.O., Schwandt P. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol. 42:1992;353-358.
25. Tikkanen M.J., Helve E., Jäättelä A., Kaarsalo E., Lehtonen A., Malbecq W., Oksa H., Pääkkönen P., Salmi J., Veharanta T., Viikari J., Äärynen M. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study. Am J Cardiol. 62:1988;35J-43.
26. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 71:1993;810-815.
27. März W., Grützmacher P., Paul D., Siekmeier R., Schoeppe W., Gross W. Effects of lovastatin (20-80 Mg Daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia. Int J Clin Pharm Therapeutics. 32:1994;92-97.
28. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. J Am Med Assoc. 256:1986;2829-2834.
29. Henwood J.M., Heel R.C. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 36:1988;429-454.
30. Cobb M.M., Teitelbaum H.S., Breslow J.L. Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs. low-fat diets. J Am Med Assoc. 265:1991;997-1001.
31. D'Agostino R.B., Kannel W.B., Stepanians M.N., D'Agostino L.C. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Am J Cardiol. 69:1992;28-34.
32. Grundy S.M., Vega G.L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 26:1985;1464-1475.
33. Tilly-Kiesi M. The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism. 40:1991;623-628.
34. Richter W.O., Geiss H.C., Sonnichsen A.C., Schwandt P. Treatment of severe hypercholesterolemia with a combination of beta-sistosterol and lovastatin. Curr Ther Res. 57:1996;497-505.
35. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts - lipid and nonlipid factors. Circulation. 81:1990;470-476.
36. Parsy D., Dracon M., Cachera C., Parra H.-J., Vanhoutte G., Tacquet A., Fruchart J.-C. Lipoprotein abnormalities in chronic haemoddialysis patients. Nephrol Dial Transplant. 3:1988;51-56.
37. Graziani M.S., Zanolla L., Righetti G., Marchetti C., Zanotto G., Lupo A. Distribution of CII and CIII peptides in lipoprotein classes - methods and clinical significance. Clin Chem. 40:1994;240-244.
38. Shepherd J. Statins: is there a need for alternative or adjunctive therapy? Br Heart J. 74:1995;13.
39. Kostner G.M., Gavish D., Leopold B., Bolzano K., Weintraub M.S., Breslow J.L. HMG-CoA reductase inhibitors lower LDL but not Lp(a) levels: a study of 24 individuals treated with simvastatin or lovastatin. Circulation. 80:1989;1313-1319.
40. Wiklund O., Angelin B., Olofsson S.O., Eriksson M., Fager G., Berglund L., Bondjers G. Apolipoprotein(A) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 335:1990;1360-1363.
41. Hunninghake D.B., Stein E.A., Bremner W.F., Greenland P., Demke D.M., Oliphant T.H. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am J Ther. 2:1995;180-189.
42. Grundy S.M., Ahrens E.H.J., Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 78:1971;94-121.
43. Beil U., Crouse J.R., Einarsson K., Grundy S.M. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism. 31:1982;438-444.
44. Denke M.A., Grundy S.M. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med. 155:1995;393-399.
45. Witztum J.L., Schonfeld G., Weidman S.W., Giese W.E., Dillingham M.A. Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. Metabolism. 28:1979;221-229.